<div id="readability-page-1"><div><p>Sunflower Pharmaceutical Group Co.,Ltd reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 1,683.98 million compared to CNY 2,966.91 million a year ago. Net loss was CNY 33.54 million compared to net income of CNY 586.84 million a year ago.</p><p>Basic loss per share from continuing operations was CNY 0.06 compared to basic earnings per share from continuing operations of CNY 1 a year ago. Diluted loss per share from continuing operations was CNY 0.06 compared to diluted earnings per share from continuing operations of CNY 1 a year ago.</p></div></div>

向日葵

<p>向日葵制药集团有限公司报告了截至 2025 年 9 月 30 日的九个月内收益显著下降。销售额从去年同期的 29.6691 亿元降至 16.8398 亿元。公司面临 3354 万元的净亏损，而去年同期则实现了 5868.4 万元的净收入。持续经营业务的基本和摊薄每股亏损均为 0.06 元，较去年每股盈利 1 元下降</p>

向日葵制药集团有限公司公布了截至2025年9月30日的九个月财务业绩